A prospective study to verify the effectiveness of a element supplement Elental for patients who are administered TS-1 after surgical resection of pancreatic cancer - Elental adjuvant S-1 trial

Toyama Hirochika0 sites35 target enrollmentFebruary 19, 2019

Overview

The number of compatible cases was extremely small and could not be analyzed.

Registry

who.int

Start Date

February 19, 2019

End Date

December 28, 2020

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Toyama Hirochika

•Eligebility Criteria during hospital state
•1\)patients 20 years old or more
•2\)proven pancreatic cancer histlogecally
•3\)confirmed by R0 or R1 surgery
•4\)PS (ECOG) between 0 and 2
•5\)wityout any prior chemotherapy and/or radiation therapy
•6\)with good oral intake
•7\)written informed consent to participate in this study
•8\)without any severe diseases and with a good condition of important organs for administration of TS\-1
•a)WBC \>\= 2,500/mm3

•Exclusion Criteria during hospital stay
•1\)with active double cancer (\*)
•\*Simultaneous double cancer or sequential double cancer whose interstitial period is shorter than 5 years.
•Carcinoma in situ or cancers localized in membranous layer are not included to double cancer.
•Cancers removed by EMR/ESD are included.
•2\)with a history of allergy against TS\-1 and/or Elental
•3\)with active infection diseases
•4\)with uncontrollable hypertension
•5\)with uncontrollable DM
•6\)with severe heart diseases clinically